Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...

Hard, measurable outcomes drive Express Scripts digital formulary

“I think that is reflective of how Express Scripts is moving forward.” The demonstration of hard clinical benefits and ROI for Express Scripts were the key elements that landed 10 digital platforms a spot on...

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on...

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...

More Waves to come on stereopure antisense oligo tech

Though the first clinical readouts from Wave’s antisense oligo platform disappointed investors, the company thinks it can parlay the learnings into improved efficacy. 2020 will offer more data readouts to support or refute the company’s...

Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

By C. Simone Fishburn, Editor in Chief While the most high profile event on Novartis’ digital health front last year was arguably its retreat from the Pear deal, CEO Vasant Narasimhan still counts going big...

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...

China a priority for Novartis’ Narasimhan

Novartis CEO Vasant Narasimhan says capitalizing on the rise of China, by prioritizing drug launches in the country, will be a key pillar of the pharma’s strategy over the next few years. A second pillar...

GSK looks to expand into MM subsets after submitting first anti-BCMA BLA

GSK is the first company out of the gate with a regulatory submission for a BCMA-targeted therapy. The ADC’s most recent response rates are lower than many programs from competing modalities against the same target...

Wave crashes on DMD data as investors await Huntington’s readout

Wave’s decision to discontinue its two Duchenne muscular dystrophy programs raised broader investor concerns about the company’s stereopure oligonucleotide platform and sent shares down more than 50% on Monday. Another readout for the platform in...

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute...